. 2023 Nov;50(Suppl 2):53-57.

doi: 10.3899/jrheum.2023-0530. Epub 2023 Jul 7.

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Ying-Ying Leung¹, William Tillett², Maarten de Wit³, Ana-Maria Orbai⁴, Laura C Coates⁵, Oliver FitzGerald⁶, Philip S Helliwell⁷, Vibeke Strand⁸, Philip J Mease⁹, Niti Goel¹⁰, Robin Christensen¹¹, Joseph F Merola¹², Christine A Lindsay¹³, Alexis Ogdie¹⁴, Laure Gossec¹⁵, Dafna D Gladman¹⁶

Affiliations

¹ Y.Y. Leung, MB ChB, MD, Duke-NUS Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; katyccc@hotmail.com.
² W. Tillett, BSc, MB ChB, PhD, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK.
³ M. de Wit, PhD, GRAPPA Patient Research Partner, Amsterdam, the Netherlands.
⁴ A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁵ L.C. Coates, MB ChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
⁶ O. FitzGerald, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.
⁷ P.S. Helliwell, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
⁸ V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
⁹ P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA.
¹⁰ N. Goel, MD, GRAPPA Patient Research Partner, and Therapeutic Area Head of Rheumatology, TrialSpark, and Duke University School of Medicine, Durham, North Carolina, USA.
¹¹ R. Christensen, MSc, PhD, Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
¹² J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹³ C.A. Lindsay, PharmD, GRAPPA Patient Research Partner, Prosper, Texas, USA, employed by Arcutis Biotherapeutics Inc.
¹⁴ A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁵ L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, Paris, France.
¹⁶ D.D. Gladman, MD, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

PMID: 37419621
DOI: 10.3899/jrheum.2023-0530

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Ying-Ying Leung et al. J Rheumatol. 2023 Nov.

. 2023 Nov;50(Suppl 2):53-57.

doi: 10.3899/jrheum.2023-0530. Epub 2023 Jul 7.

Authors

Affiliations

¹ Y.Y. Leung, MB ChB, MD, Duke-NUS Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; katyccc@hotmail.com.
² W. Tillett, BSc, MB ChB, PhD, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK.
³ M. de Wit, PhD, GRAPPA Patient Research Partner, Amsterdam, the Netherlands.
⁴ A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁵ L.C. Coates, MB ChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
⁶ O. FitzGerald, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.
⁷ P.S. Helliwell, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
⁸ V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
⁹ P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA.
¹⁰ N. Goel, MD, GRAPPA Patient Research Partner, and Therapeutic Area Head of Rheumatology, TrialSpark, and Duke University School of Medicine, Durham, North Carolina, USA.
¹¹ R. Christensen, MSc, PhD, Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
¹² J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
¹³ C.A. Lindsay, PharmD, GRAPPA Patient Research Partner, Prosper, Texas, USA, employed by Arcutis Biotherapeutics Inc.
¹⁴ A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁵ L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, Paris, France.
¹⁶ D.D. Gladman, MD, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.

PMID: 37419621
DOI: 10.3899/jrheum.2023-0530

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (MDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID3). Further appraisal of candidate composite instruments is ongoing.

Keywords: GRAPPA; composite outcome measures; outcome measures; physical function; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Cited by

Filling the "GAP" in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint.
Tillett W, Birt J, Vadhariya A, Ross S, Ngantcha M, Ng KJ. Tillett W, et al. Rheumatol Ther. 2024 Oct;11(5):1101-1114. doi: 10.1007/s40744-024-00690-1. Epub 2024 Jul 2. Rheumatol Ther. 2024. PMID: 38955921 Free PMC article.
Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity.
Ramsay H, Johnston RV, Cyril S, Glennon V, Grobler L, Burgess DM, McKenzie BJ, Whittle SL, Buchbinder R. Ramsay H, et al. Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD015880. doi: 10.1002/14651858.CD015880. Cochrane Database Syst Rev. 2024. PMID: 39679815 Free PMC article.
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.
Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Singla S, et al. RMD Open. 2024 Jan 8;10(1):e003809. doi: 10.1136/rmdopen-2023-003809. RMD Open. 2024. PMID: 38191215 Free PMC article.
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study.
López-Medina C, Gorlier C, Orbai AM, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Meisalu S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L. López-Medina C, et al. Rheumatology (Oxford). 2025 May 1;64(5):3090-3094. doi: 10.1093/rheumatology/keaf002. Rheumatology (Oxford). 2025. PMID: 39752329 Free PMC article.
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.
Kavanaugh A, Mease P, Gossec L, Ranza R, Tsuji S, Douglas K, Lane M, Lippe R, Mittal M, Gao T, Setty A, Ciecinski S, Aletaha D, Nash P. Kavanaugh A, et al. ACR Open Rheumatol. 2024 Nov;6(11):736-745. doi: 10.1002/acr2.11714. Epub 2024 Aug 1. ACR Open Rheumatol. 2024. PMID: 39087872 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Affiliations

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous